

Daniel Rodríguez Ajamil ESR13 Fellow

Institution: Tel Aviv University
Group: Cancer Research and Nanomedicine
Supervisor: Daniel Rodríguez Ajamil
E-mail: danielra151920@gmail.com

Meeting 2
Edinburgh, 3rd February 2020


Bioorthogonal Catalysis for BRCA Mutated Breast Cancer

HR-/HER2-

— — — — Aka “Triple
Negative

15% of all breast cancers (TNBC)”

- Difficult to target therapeutically
- Current therapy: surgical resection and removal of auxiliary lymph nodes, with postoperative systemic chemotherapy.
- **1/3 of TNBC carry BRCA1 or BRCA 2 mutations**




**Defective DNA repair
mechanisms**

Increases 70% cancer prob.





**Therapeutic Opportunity:
Synthetic Lethality**

PARPi




OLAPARIB (Anti-Proliferation effect)




N=3

OLAPARIB VS. TALAZOPARIB




IC50 ca. 1 uM



IC50 ca. 1,2 nM

N=3


EMT-6 cells PD-L1 expression under Talazoparib treatment



Marker	X-Med
Tal. 1uM	2,421.67
Tal. 10nM	2,421.06
Tal. 0.1nM	1,084.52
Control	1,096.83
Sec. Only	163.63
Unstained	204.34


- EMT6 cells have high basal expression of PD-L1
- PD-L1 expression increases with the concentration of the Talazoparib treatment

EMT-6 cells PD-L1 expression under Talazoparib treatment



- EMT6 cells have high basal expression of PD-L1
- PD-L1 expression increases with the concentration of the Talazoparib treatment
- PD-L1 expression increases with the temporal exposure to Talazoparib

EMT-6 cells PD-L1 expression under ID56 treatment




- PD-L1 signal decreases with the Treatment of ID56 (1uM)
- After 72h the expression of PD-L1 drastically increases.

Marker	X-Med
anti PD-L1 (ID56) 72h	1,137.67
anti PD-L1 (ID56) 48h	233.92
anti PD-L1 (ID56) 24h	308.41
Control	478.40
Secondary only	200.59
Unstained	143.44

anti PD-L1 (ID56) 72h	1,137.67
anti PD-L1 (ID56) 48h	233.92
anti PD-L1 (ID56) 24h	308.41
Control	478.40
Secondary only	200.59
Unstained	143.44


EMT-6 cells PD-L1 expression under ID56 treatment



- PD-L1 signal decreases with the Treatment of ID56 (1uM)
- After 72h the expression of PD-L1 drastically increases.
- PD-L1 signal decreases with the Treatment of ID56 (1uM) also when is combined with Talazoparib (10nM)


C12-Talazoparib PEG Dendron Hybrids

PEG-C12 Hybrid




Tests Measurements

GPC	1.039
DLS	31.6 ± 6 nm
CMC	3±1 µM




Free Talazoparib



IC50 ca. 1,2 nM

C12-Talazoparib



IC50 ca. 2 nM




C12 Internalization in EMT6 3D Spheroids

1h




3h

24h


C6-Cy5




C12-Cy5





Excitation Cy3 in 488 nm



C12 Internalization (FACS)



EMT-6 C12 3h FRET






C12 Internalization (Confocal)






FRET Micelles (Cy5 Channel) Cy3 Micelles (Cy3 Channel) FRET Micelles (Cy3 Channel)

Before
Bleaching



After
Bleaching




C12 Internalization (Confocal)

$$FRET(\%) = \left(\frac{I_1 - I_0}{I_1} \right) \times 100$$



I_1 = Intensity after bleaching

I_0 = Intensity before bleaching




- The C6 Micelles seem to internalize faster than C12 micelles
- After 3 hours of Micelles incubation with EMT6 cells, the C12 micelles showed more FRET effect, probably due to their lower CMC values (3uM for the C12 vs. 4 uM for the C6)
- The Micelle-monomer equilibrium moves towards the monomer state during the interaction with the membrane, or micelles require longer internalization times than the monomers

P-Selectin Expression in EMT6 spheroids



Marker X-Med	
All	779.54
All	311.18
All	160.59

Local training



Network-wide training 2019

